Overall, prospective clinical studies on HPV‐positive HNSCC patients need to be conducted to demonstrate the antitumour efficacy of targeting agents in light of the molecular alterations identified as companion biomarkers (PDL1 and MYC) in the present study. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.